Skip to main content

ReVIDA® Recovery Publishes Article Explaining How to Win the War Against Opioids

Fort Sanders, Tennessee -

Knoxville, TN – ReVIDA Recovery® in Knoxville is weighing in on Appalachia’s opioid crisis with a newly published article entitled “Suboxone® (Buprenorphine): A Powerful Tool in the War Against Opioids.”

Appalachia, a southern cultural region that spans over 400 counties, currently has an overdose mortality rate that is 72% higher than the rest of the United States. ReVIDA Recovery®, located in Knox County TN, is in one of these counties. This article explains some of the reasons why this region is at the center of the opioid crisis. Poverty, occupational hazards, cultural values, and mindsets contribute to these statistics.

15% of these Appalachian counties are currently living in poverty, and over 75% of resident coal mining communities are working in substandard environments. Additionally, Appalachian residents are independent and prone to handling medical issues themselves rather than reaching out to a physician. All of these things may contribute to worsening addiction and overdose mortality rates.

ReVIDA Recovery® in Knoxville believes that Suboxone® (buprenorphine), a medication that is FDA-approved for treating opioid addiction, is a valuable tool in fighting opioid use disorder (OUD). “The fact of the matter is that some methods, such as traditional 12-step programs, don’t work for everyone. Medication is often needed for managing withdrawals, cravings, relapse, and overdose. Suboxone® (buprenorphine) is one of the best weapons we have against the opioid crisis because it has been clinically proven to help with all of these stumbling blocks. It’s also FDA-approved in the treatment of OUD – something that is often overlooked,” the article states.

ReVIDA Recovery® also writes that a large reason why Suboxone® (buprenorphine) isn’t used more is because of the stigma associated with it. They write that some people believe Suboxone® (buprenorphine) is simply substituting one opioid for another when in reality, it is part of a clinically-proven, medication-assisted treatment program. Others believe Suboxone® (buprenorphine) is similar to “giving up” on sobriety, but a study in the Journal of the American Medical Association (JAMA) disproves that. The study showed improved patient outcomes in those who took Suboxone® (buprenorphine) in treatment, versus those that followed traditional detox or 12-step methods.

Other misconceptions surrounding treatment with Suboxone® (buprenorphine) include the idea that Suboxone® (buprenorphine) gets people “high” (it does not), it will not work with other recovery programs (it works well alongside other treatment plans), and that patients will sell Suboxone® (buprenorphine) on the street for money. Illicit sales of Suboxone® (buprenorphine) are not unheard of, but ReVIDA Recovery® has processes in place to mitigate this.

One of ReVIDA Recovery®’s primary missions is to fight the stigma surrounding Suboxone® (buprenorphine) because they believe it can save countless lives and lower overdose mortality rates. “ReVIDA® is a company that cares deeply about practicing evidence-based methods of treatment and executing those methods with compassion. To win the war on opioids, the battle of stigma must be waged – and ReVIDA® Recovery is one of its key warriors,” the article states.

To learn more about how ReVIDARecovery® is fighting stigma or to inquire about their programs, Knoxville residents can call them at 865-412-8090 or visit their website. The mission at ReVIDA® Recovery is to help Tennessee residents reclaim their lives from opioid use disorder through evidence-based treatment and high-quality addiction care.

###

For more information about ReVIDA Recovery® Knoxville, contact the company here:

ReVIDA Recovery® Knoxville
865-633-0353
generalinfo@revidarecovery.com
2001 Highland Ave
Knoxville, TN 37916

FacebookTwitterGoogleDiggRedditLinkedIn

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.